Pioneering the New Era of Nanoparticle Formulation & Medical Device Technology

Better & Faster Biotechnology

Nanoparticle Formulation Technology

Accelerated Drug Development Strategy

By leveraging our product development expertise and core technology, we mitigate the high costs and risks associated with basic research on new chemical entities. Instead, we reformulate readily available compounds with established safety and efficacy profiles for oncology and periodontal treatments. This strategic approach accelerates drug development and significantly condenses regulatory approval timelines.

Advanced Periodontal Technologies

Our finalized periodontal products utilize PLGA polymer-based nanoparticle drugs for subgingival application. PLGA is an FDA-approved, biodegradable, and highly biocompatible polymer.

Pipeline Optimization & Formulation Expertise

Beyond periodontal care, our early-stage pipeline includes a promising nanoparticle therapeutics platform. To ensure safety and efficacy, our team of PhD formulation scientists optimizes drug candidates across several critical checkpoints:

Biocompatibility & Toxicity: Ensuring safe interaction with human tissue.
Drug Delivery: Optimizing drug loading and controlled release.
Stability: Enhancing nanoparticle storage and shelf-life.
Targeting: Improving biodistribution, organ/tissue selectivity, and cellular internalization.
Biodegradability: Guaranteeing safe breakdown within the body.

Driving Clinical Trial Success

Mastering these checkpoints ensures our polymer-based formulations are safe and highly effective. Ultimately, our deep formulation expertise provides a reliable blueprint for early-stage nanotherapeutic development, maximizing the success rate of our formulations as they enter clinical trials.

Versatility in Anesthetic Injections

Our patented technology and business objective is to reduce pain and efficiency of dental local anesthetic injections for patients. Our primary focus is on the development, regulatory approval, and commercialization of an improved local dental anesthetic drug that is less painful, faster-acting, and more reliable.

Our success is based on the comprehensive development of a winning regulatory strategy to help build a crucial framework for the overall development plan and aid in determining the fastest execution.

Multiple-dose, Automated-dosing and Single use-disposable Periodontal Devices

Our research is driving tangible innovations that will redefine the periodontal market. Through our active projects, we are developing an advanced platform for localized therapy that delivers faster, more accurate, and highly effective periodontal treatments.

Backed by our mission of "helping people live longer," our patented devices leverage advanced technology to help patients maintain healthy gums for life.

Since 2014, we have been dedicated to solving the most fundamental challenges in periodontal care. By channeling our transformative technologies through a comprehensive regulatory strategy, we are significantly improving the entire periodontal workflow.

We develop and integrate FDA-regulated nanoparticle drug formulations and medical devices, designing each product with the entire end-user ecosystem in mind

We are dedicated to advancing healthcare through the development of next-generation therapeutics, targeted drug delivery systems, and innovative medical devices that provide superior treatment options and elevate the standard of patient care.

Empower Growth

In 2023, we received FDA clearance on our first standalone medical device. In 2027 we are expected to receive FDA approval for our first two finished periodontal drug products.

As our team prepares for success to meet the high demand for periodontal disease around the Globe, we continue working on expanding our clean room facility in Florida to meet expected demand domestic and international demand.

In the U.S., “one out of every two American adults aged 30 and over has periodontal disease” according to the Centers for Disease Control and Prevention (CDC). Across the globe, periodontal disease is the single most prevalent chronic infectious disease.